Form 4: Exelixis EVP Aftab Vests Performance Stock Units

Exelixis EVP of Research and Development, Dana Aftab, vested 119,578 performance-based restricted stock units, with a portion withheld for taxes.

Summary

• Dana Aftab, Executive Vice President of Research and Development at Exelixis, Inc., vested 119,578 shares of common stock from a performance-based restricted stock unit (PSU) award.
• This vesting occurred on January 15, 2026, following the Compensation Committee's certification that certain performance criteria had been achieved.
• The original PSU award, granted on April 3, 2023, covered 68,331 target shares, with a potential for vesting up to 175% of target shares based on the timing and level of performance achievement.
• The Committee determined that performance criteria were achieved, resulting in eligibility for 175% of the target shares (Achieved Shares).
• 50% of these Achieved Shares, totaling 119,578 shares, vested immediately on January 15, 2026.
• The remaining 50% of the Achieved Shares are scheduled to vest on February 15, 2027, contingent upon Dana Aftab's continuous service through that date.
• 27,254 shares were withheld by Exelixis, Inc. to satisfy tax obligations related to this vesting event, at a price of $45.23 per share.
• Following these transactions, Dana Aftab directly beneficially owns 733,102 shares of Exelixis, Inc. common stock.
• Additionally, 5,835 shares are indirectly owned through the Exelixis, Inc. 401(k) Plan, as per a plan statement dated January 14, 2026.
• Beneficial ownership also includes 491,096 shares of common stock that will be issued upon the future vesting of restricted stock units (RSUs) and One-Time Award PSUs granted on March 31, 2025.

Sentiment

Score: 7

Explanation: The filing reports the successful vesting of performance-based equity awards for a key executive, indicating the company met its performance targets. This is a positive sign for operational execution and executive retention, though it's a routine compensation event rather than a new strategic announcement.

Positives

• The Compensation Committee certified the achievement of certain performance criteria, indicating strong company performance in the relevant period.
• A significant equity award vested for a key executive, Dana Aftab, aligning management incentives with shareholder value and demonstrating executive retention.

Future Outlook

The remaining 50% of the achieved performance-based restricted stock units (119,578 shares) are expected to vest on February 15, 2027, contingent upon the reporting person's continuous service through that date.

Industry Context

This filing reflects a standard executive compensation event within the biotechnology/pharmaceutical industry, where performance-based equity awards are common tools to incentivize and retain key talent. The vesting indicates the company met specific internal performance targets, which is generally a positive signal for operational execution.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) with a maximum payout of 175% of target shares is a common practice in the biopharmaceutical industry for executive compensation. This structure aligns executive incentives with long-term company performance, similar to compensation plans observed at peer companies like Amgen, Gilead Sciences, or Biogen, which also utilize multi-year performance cycles and potential for above-target payouts for exceptional results.
• The tax withholding mechanism is also standard for equity compensation in the industry.

Stakeholder Impact

• Shareholders: This event signals successful achievement of company performance targets, which is generally positive. It also demonstrates alignment of executive incentives with shareholder value.
• Employees: The successful vesting of performance-based awards can reinforce confidence in the company's equity incentive plans and its commitment to rewarding performance.
• Management: Dana Aftab's compensation is enhanced, further aligning her interests with the company's long-term success.

Next Steps

• The remaining 50% of the achieved PSU shares (119,578 shares) are scheduled to vest on February 15, 2027, subject to continuous service.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event where performance-based stock units vested due to the achievement of pre-defined company performance criteria. While the successful vesting is a positive indicator of operational execution and management alignment, it does not present new information that would fundamentally alter the investment thesis for Exelixis. Investors should continue to hold based on broader company fundamentals and future prospects, as this filing alone does not warrant a change in recommendation.

Keywords

Exelixis, EXEL, Form 4, Insider Transaction, Stock Vesting, Performance Stock Units, Executive Compensation, Equity Incentive Plan, Dana Aftab